QIAGEN enters into a Supply Agreement with AstraZeneca
Venlo, The Netherlands, June 30, 2004 - QIAGEN N.V. (NASDAQ: QGENF; Frankfurt, Prime Standard: QIA) a leading supplier of products and technologies for nucleic acid separation, purification and handling today announced that it has entered into a supply agreement for siRNA molecules with AstraZeneca (NYSE: AZN). Under the terms of this agreement QIAGEN will be the preferred supplier to AstraZeneca for siRNA products used in gene silencing applications. Financial terms were not disclosed.
"We are pleased that AstraZeneca has chosen QIAGEN as its preferred supplier for RNAi based gene silencing experiments", said Dr. Ulrich Schriek, QIAGEN's Vice President Corporate Business Development. "QIAGEN's proprietary siRNA design based on TOM-amidites in combination with its state-of-the-art synthesis technologies provide best standards in quality and purity as well as highest efficiencies in cost and time and fully addresses in both research as well as large-scale applications. In addition to siRNA molecules, QIAGEN provides an integrated product solution covering RNA sample handling and preparation, siRNA delivery, and the set-up of down stream analysis. This agreement with AstraZeneca further strengthens QIAGEN's position in the pharmaceutical industry for its siRNA offering."
About Qiagen in RNAi:
RNAi is a powerful discovery tool of biomedical research using siRNA segments to turn off or "silence" a specific gene to study gene expression patterns as well as the impact of specific expression profiles directly on a cell or an entire organism. QIAGEN's patented siRNA synthesis based on TOM-amidites chemistry provides highest quality and purity of RNA oligonucleotides. QIAGEN's siRNA products combined with QIAGEN's robotic platforms, RNA transfection, -purification and -amplification technologies provide fully integrated solutions for gene silencing in the most dynamic area of today's functional genomics markets.
QIAGEN N.V., a Netherlands holding company with subsidiaries in Germany , the United States , Japan , the United Kingdom , Switzerland , France , Italy , Australia , Norway , Austria , Canada , and the Netherlands believes it is the world's leading provider of innovative enabling technologies and products for the separation, purification and handling of nucleic acids. The Company has developed a comprehensive portfolio of more than 320 proprietary, consumable products for nucleic acid separation, purification and handling, nucleic acid amplification, as well as automated instrumentation, synthetic nucleic acid products and related services. QIAGEN's products are sold in more than 42 countries throughout the world to academic research markets and to leading pharmaceutical and biotechnology companies. In addition, the Company is positioning its products for sale into developing commercial markets, including DNA sequencing and genomics, nucleic acid-based molecular diagnostics, and genetic vaccination and gene therapy. QIAGEN employs approximately 1,400 people worldwide. Further information on QIAGEN can be found at http://www.qiagen.com/.
AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world's leading pharmaceutical companies with healthcare sales of over $18.8 billion and leading positions in sales of gastrointestinal, oncology, cardiovascular, neuroscience and respiratory products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global and European) as well as the FTSE4Good Index. Worldwide, AstraZeneca has six major research and development sites, four discovery facilities and a clinical research site, in total, employing more than 11,500 R&D staff members in Canada , France , India , Japan , Sweden , United Kingdom and the United States . For more information please visit www.astrazeneca.com
Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations and risks of dependency on logistics), variability of operating results, the commercial development of the DNA sequencing, genomics and synthetic nucleic acid-related markets, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's, products (including seasonal fluctuations), difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate its products from competitors, and the integration of acquisitions of technologies and businesses. For further information, refer to the discussion in reports that QIAGEN has filed with the U.S. Securities and Exchange Commission (SEC).
IR QIAGEN N.V.
Tel.: +49 2103 29 11710
Fax +49 2103 29 21710